

Autumn Partnering Day 15th China Pharma & Medtech BD Summit

Sept. 24–25, 2020, Online to Offline (Qingdao, China)

The Largest Online Corporate Access Event Between China And Western Biopharma Industry



Register Now!







Invitation

We cordially invite you to join our "ACCESS CHINA Forum - Autumn Partnering Day | 15th China Pharma & Medtech BD Summit" to be held online and offline in Qingdao, China on September 24th-25th. This year's Qingdao Forum expects to have over 500 BDs from top pharma companies and VCs participating on site and more companies will join vitually online.

ACCESS CHINA events offer companies corporate access through our proprietary platform, which covers 2,000+ BD directors and executives from Chinese biopharma, healthcare, and investment firms. Presenting and participation are FREE-OF-CHARGE.

China Pharma & Medtech BD Summit is an annually grand event organized for BDs from top pharma companies operating in China to gather and socialize. The event has become an influential forum within China's Pharma and MedTech sector after hosting it consecutively for the past 15 years.

As part of the 15th *China Pharma & Medtech BD Summit*, *ACCESS CHINA* Autumn Forum will help western biopharma companies efficiently present their assets not only online but also in front of 500+ healthcare companies and VCs on site. During the event, audiences can have access to innovative biopharma and healthcare products from China, Europe, US & Asia.

We look forward to welcoming you at our Autumn event in Qingdao and online!

Sincerely,

ACCESS CHINA Forum Organizing Committee

CO-ORGANIZERS















About 15th China Pharma and MedTech BD Summit

The 15th China Pharma and MedTech BD Summit (Qingdao, Sept. 24-25, 2020) is a grand event for business development within the comprehensive healthcare industry. The event has become an influential forum within China's Pharma and MedTech sector after hosting it consecutively for the past 15 years. The BD Summit is a place where elites in various fields of pharma business development will be gathered, new thoughts will be emerged as well as transactions.

The Event is organized by CHBD, which is a leading non-profit organization of BDs from top pharma companies operating in China. With about 1,000 active members from the pharma industry, CHBD organizes different events throughout the year to help the communications of pharma BDers.



Speakers (Partial)



Jin Wang Global Managing Partner Mckinsey



Yibo Cao Managing Director Sequoia Capital



Yaping Shen Vice General Manager Hengrui Pharma



Danjie Huang BD Director Bayer (China)



Wenjun Sun
CCO
JW Therapeutics



Shuyuan Yao Vice President WuXi AppTec



Guang Yang Investmation GM Grand Enterprises



Mingming Yan BD Head & VP Kintor Pharma

Full Agenda see next page



China BD Summit 15-Year History

China BD Summit, organized by CHBD, has become an influential forum after hosting it consecutively for the past 14 years. Each year, one or two member companies of CHBD volunteer to co-organize the event. This year, the event is co-organized by Baheal Pharma. The previous one was co-organized by Luye Pharma & Winhealth Pharma.



China BD Summit past events at a glance









	September 24 th (Thursday) Agenda
9:00-9:10	Opening Speech: Kui Wang, Secretary General (CHBD)
9:10-9:20	Welcome Speech: Gang Fu, President (Baheal Pharmaceutical Group)
TRACK ONE: TRENDS AND	OPPORTUNITIES
9:20-9:40	Outlook of China's Pharmaceutical Industry Trend Jin Wang, Global Managing Partner (Mckinsey)
9:40-10:00	Health Innovation and Ecology in China Wei Zhang, Former Chief Strategy Officer (WuXi AppTech)
10:00-10:20	VBP era, Where Original Research Presciption Drug Marketing Goes? Yuan Zhang, Vice President (Baheal Pharmaceutical Group)
10:20-10:50	Roundtable: New Opportunities for Chinese Pharmaceutical Enterprise Host: Xin Wang, Head & Director (Servier Asia Innovation Center) Guests: Yaping Shen, Vice General Manager (Hengrui Pharma) Xianghong Shao, Partner (Jinhailing Capital) Yibo Cao, Managing Director (Sequoia Capital) Jia Xu, Partner, Pharmaceutical Sector (PwC)
TRACK TWO: CAPITAL AN	D MARKETS
11:00-11:15	New Opportunities for Medical Investment Brought by Sci-Tech Innovation Board Jiaxi Xu, Pharmaceutical Chief (Industrial Securities)
11:15-11:30	Review of Cross-border Licensing Transactions Lei Zhou, Partner (Global Law Office)
11:30-12:00	Guests Sharing Roundtable: How to Promote Innovation in Chinese Pharmaceutical Industry Host: Li Zhang, Partner (CDH Innovation and Growth Fund) Guest: Ping Huang, Director (FountainVest) Bing Guan, Managing Director (HuiEn Capital) Kun Yang, Managing Director (Sdic Venture Capital) Chao Wu, Managing Director (Vigintillion Capital)
12:00-13:00	Networking Lunch
TRACK THREE: NEW TECH	NOLOGY AND NEW VISION
13:00-13:20	Prospect of Cell Therapy Shuyuan Yao, Vice President (WuXi AppTec)
13:20-13:40	The Prospect of New Vaccine Technology Hangwen Li, Founder & CEO (Stemirna)
13:40-14:10	Roundtable: How to Integrate Technology with China's Pharmaceutical Industry Host: Guang Yang, General Manager of Investment Department (Grand Enterprises) Guest: Guodong Jia, General Manager (Obio Technology) Xiaokun Shen, Founder & CEO (Convalife) Zilong Wang, Business Development Director (Walvax Biotechnology) Wenjun Sun, Chief Commerical Officer (JW Therapeutics)
TRACK FOUR: POLICY AND	O OUTLOOK
14:10-14:30	Al Driven SCRM System New Mode of Marketing Guowei Yan, President (Qing Yun Technology)
14:30-14:50	The Trend Outlook of Chinese Medicine Policy Matthew Chervenak, Founder & CEO (GBI)
14:50-15:20	Roundtable: How to Transform Enterprises under New Medical Policy Host: Weiting Wang, Vice President (Baheal Pharmaceutical Group) Guest: Mingming Yan, Business Head & Vice President (Kintor Pharmaceutical) Shenglong Wu, Senior Vice President (KPC Pharmaceuticals) Wei Ding, Cheif Business Operator (Zelgen Biopharmaceuticals) Jin Zhao, Vice President (Tianshili Biopharmaceuticals)
15:20-15:40	Tea Break
TRACK FIVE: GLOBALIZATI	ION AND LOCALIZATION
15:40-15:50	ACCESS CHINA Elevator Pitch
15:50-16:00	Progress in the Internationalization of Chineses Medicines Sean Jiang, Founder & CEO (YAFO Capital)
16:00-16:20	The Development Strategy of Chinese Pharmaceutical Companies from the Global Perspective Wenjie Zhang, President (Henlius)
16:20-16:50	Roundtable: Intergration of Globalization and Localization Host: Peirong Tong, Director (GSK China Channel Cooperation development) Guest: Yi Wai, China Business Development Director (Abbott Pharmaceuticals) Zhengye Wang, Senior Vice President (BrightGene) Danjie Huang, Business Development Director (Bayer Pharma China) Ping Cao, Busiess Development Vice President (Henlius)
16:50-17:50	Sharing of Innovative Enterprises (Baheal Pharmaceutical Group, BrightGene, Simcere, Convalife, etc.)
17:50-18:00	Closing Remark, Jiguo Zhang, Chairman (CHBD)
17.50 10.00	Sissing homany signs zhang, challinan (Chibb)



About ACCESS CHINA Forum


ACCESS CHINA Forum is the most effective deal-making platform for Western pharma and biotech leaders looking to enter or expand in the Chinese market. Access China creates invaluable BD opportunities by directly connecting and meeting with the right partners for development, licensing or commercial collaborations.

The events offer companies online corporate access through our proprietary platform, which covers 2,000+ BD directors and executives from Chinese biopharma, healthcare, and investment firms.



Application process

To apply for a "presenting slot", you simply need to submit (1) a filled registration form along with (2) your corporate presentation for our Event Committee to review. Once approved, you will offer the chance to present on in-person roadshows in China after carefully review. Presenting slots will be given out on a first come, first served basis.



ACCESS CHINA Online Partnering Day 3-Step Process

Step 1. **Presentation Submission &** Review

Company submits 25+ minutes presentation and asset descriptions with interests & goals in China (licensing, capital raising, M&A, etc).

ACCESS CHINA Committee will review the opportunity in the related therapeutic areas.

Step 2. Online

YAFO Life Science banking team help you prepare the presentation on live day and collect interests from targeted Chinese investors in Presentation on the related therapeutic areas.

> If interest is high, webinar will be organized with interested Chinese parties. Presentation replay will be organized 7 days afterwards.

> YAFO will collect interests and feedbacks while facilitating the potential transaction after the conference.

Step 3. China Roadshow & **Deal Closing** YAFO will arrange 1-week China roadshow with serious investors (for engaged clients only)

Facilitate the signing of LOI/Term Sheet, Due Diligence, and closing of the transaction


JOIN US WHEN YOU ARE READY

For Global Biopharma Companies

No need to wait for months to spend time and money for a physical event in China. As ACCESS CHINA has several Online Partnering Day events through the year, you are welcome to join us when you are ready.

For Chinese Biopharma Companies

ACCESS CHINA has strong coverage of pharmaceutical and biotech companies from North America, Europe, MENA, Japan, Korea, and etc. This offers you an ideal channel to meet with potential out-licensing or commercial partners in different regions.





LIVE DAY

During the live showcase held at ACCESS CHINA Online Partnering Day, presenters can discuss their pipeline, R&D activities, fundraising goals, and expectations from China market. Event audiences will come from 2,000+ BD Directors & Executives from biopharma companies and PE/VCs.

REPLAY DAY

For investors missing the live presentations, a replay-day will be arranged one week later. This will give the presenters even broader exposure.

Not just another conference, you have a strong banking team supporting you!

YAFO Life Science Banking Team



Sean Jiang, CFA CEO & Founder

20+ years Wall Street banking & investment experience with Roth Capital, Xiangcai Securities, etc.. Former China GM of ISI Group (Evercore).



William Yao Partner Asset In-licensing

30 years+ healthcare experience, including 7+ years in AstraZeneca China. Co-founder of Cyberpharm Investment & Sino-Octa; former doctor at Renji Hospital.



Qi Li China BD Director

Pharma industry analysis and investment banking (M&A, Licensing). 15+ Crossborder transactions experience.



Fan Zheng Managing Director China Execution

Extensive involvement and expertise in 30+ global life science licensing & cross border financial transactions. Former analyst at Roth Capital.



Andy Sun Partner Licensing

18 years experience in pharma R&D, BD & licensing, and investment in life science industry, including CASI Pharma, Tianjin Chase-sun Pharma, etc.



Gian Dell Antonio BD Manager London Office

Pharma industry analysis and investment banking (M&A, Licensing). Former research analyst at PE Lab SDA Bocconi.



Kun Tao, CFA Partner US Operations

20+ years of Wall Street experience in equity research and cross-border pharma licensing/investment with Roth Capital, Connective Capital, and Acorn.



Steve Engen
Partner , US & Japan
YAFO-Renexes

20+ years of Japanese and US biopharma industry experience with Shire, Solasia Pharma, Mundipharma, etc., brought 10+ US pharma products to the Japanese market.



Wendi Xiang Vice President

Cross border transaction analyst and fund administrator. BA, University of Nottingham; MA, University of Warwick.



Kui Wang Partner M&A, Out-licensing

20+ years pharma BD experience with Eisai, EddingPharma, Winhealth Pharma, LEO, Hemony, etc. 50+ pharma & crossborder deal closing experience.



Dr. Mathias Schott Director , Europe YAFO-FCF

7+ years of european biotechnology and medtech capital raising & M&A industry experience. Mathias is also co-author of several LS capital markets publications.



Michelle Liu Analyst

Extensive involvement in 5+ Crossborder transactions. BA, University of Oregon.



3119

800+

150+

Companies

Views

Requests

Assets

- Presenting Companies: 35 companies from 13 countries.
- ❖ Total audience: <u>2678 viewers</u> for 35 presenting companies.
- Follow-up meetings: 800+ requests for asset presenting opportunities.
- Assets: 150+ assets looking for China or global partnering or funding.





The Largest Online Corporate Access Event between China & Western Biopharma Industry 助力中国药企全球BD









LIFESCI ADVISORS





淘 科 技










PLUS THERAPEUTICS

Nuv

T actical

DYADIC°



10:00 AM Plus Therapeutics

Mr. Russ Havranek, VP 10: 30 AM NuvOx Pharma

Mr. John McGonigle, Director of BD

11: 00 AM Tactical Therapeutics, Ir Dr. Rashida Karmali, CEO

iumasonix

12: 00 PM Lumasonix Inc.

11:30 AM Dyadic Internatingal

Mr. Morris Smith, VP Partnerships & Product

2: 30 PM KEYNOTE SPEECH Patent Considerations in Biomedical Product Evaluation

Mrs. Ping Rawson, CFO

Akamara

3: 00 PM ImmunoBiochem

Dr. Anton Neschadim, CEO 3:30 PM Akamara Therapeutics Mrs. Susan Graf. CEO

4:30 PM Soligenix, Inc

4:00 PM Golden Biotechology Corporation GoldenBiotech Dr. Today Su, CEO

\chi ixbiopharma

XXgenenta

(SOLIGENIX

Mr. Daniel Ring, V.P. BD & Strategic Planning 5:00 PM ix Biopharma Ltd

Mrs. Eva Tan, Director, Corporate & Commercial Strateg

5:30 PM Genenta Science Mr. Pierluigi Paracchi, Chairman & CEO













Biophysical Therapeutics













